Skeletal and Adipose Tissue Engineering with Adipose-Derived Stromal Cells by Hyun, Jeong S et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Skeletal and Adipose Tissue Engineering with 
Adipose-Derived Stromal Cells 
Jeong S Hyun, Emily R Nelson, Daniel Montoro,  
Benjamin Levi and Michael T. Longaker 
Stanford University  
United States of America  
1. Introduction 
There are wide ranges of pathologies leading to critical adipose and skeletal tissue loss 
including trauma, cancer resection and congenital anomalies. With half of the adult 
population in the United States estimated to be affected by a chronic disease according to the 
World Health Organization, the biomedical burden for replacement tissue continues to rise. 
By 2030, the number of adults over the age of 65 is expected to double to over 70 million in 
the United States (Institute of Medicine, 2008). The use of autologous tissue grafts and 
allografts for multiple organ systems have been successfully employed clinically, however 
many inherent disadvantages to these strategies exist including graft failure, infection, 
donor site morbidity etc. (Becker et al. 2011). While synthetic materials are not limited by 
availability, they are prone to infection, rejection, and breakdown over time (Keefe, 2009).  
Due to these inherent limitations, true regenerative medicine remains the ultimate goal for 
tissue replacement.  
In 2001, researchers isolated a new population of adult multipotent cells in lipoaspirate 
(Zuk, et al. 2001, 2002).  Since the discovery of adipose-derived stromal cells, a tremendous 
amount of work has been done in characterizing this population of cells and defining their 
capacity for multipotent differentiation. Adipose-derived stromal cells have potential 
advantages over other types of stem cells such as mesenchymal stem cells in that they are 
widely available and easily harvested through a simple liposuction procedure without 
altering their viability. Adipose-derived stromal cells can differentiate into mesodermal cell 
lines and offer a broad range of possibilities for application within the field of tissue 
engineering. These cells have already been put through several clinical trials in the 
treatment of a diverse array of pathologies including ST-elevated myocardial infarctions, 
Crohn’s fistulas, and spinal cord injuries (Clinical Trials.gov, 2011).  
Bone regeneration is an area of great interest in the field of tissue engineering. Over sixty 
million Americans are expected to be diagnosed with osteoporosis or low bone mass by the 
year 2020 (Samelson & Hannon, 2006). This can generate critical pathology as 1 in 2 women 
and 1 in 4 men over the age of fifty experiences an osteoporotic fracture in their lifetime 
(National Osteoporosis Foundation, 2011). With limited availability of autologous bone 
grafts, a bioengineered tissue replacement would be an ideal clinical alternative. Adipose-
derived stromal cells were shown early on to have the capability for osteogenic 
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differentiation in vitro (Gimble & Gullak, 2003) and the ability differentiate into osteogenic 
tissue in vivo (Cowan & Longaker, 2004, Cowan & Longaker, 2005). With adipose-derived 
stromal cells osteogenic capability defined, research has focused on identifying specific 
methods and pathways that enhance the osteogenic capability of adipose-derived stromal 
cells. In this chapter, we will focus on the major pathways involved in osteogenic 
differentiation and their modulation to allow for greater osteogenic capability for skeletal 
tissue engineering.  
A critical aspect in skeletal tissue engineering is the ability for the implanted cells to 
function within the three-dimensional structure of the surrounding skeleton. The implanted 
cells must have the proper biomechanical characteristics of bone to allow it to have the form 
and function necessary for successful skeletal regenerative tissue. The development of 
scaffolds with osteoinductive properties has allowed for cells to be placed within a three-
dimensional structural environment mimicking the skeletal system. These scaffolds provide 
an environment or niche for cell differentiation and integration within the surrounding 
tissue and promote the proper healing of the skeletal defect. In this chapter, we will discuss 
several of the major synthetic scaffolds being used in skeletal tissue engineering and how 
certain scaffold properties can enhance osteogenic healing within the skeletal defect. 
Another potential clinical application of adipose-derived stromal cells with tissue 
engineering is their use for soft tissue replacement. Of particular importance is the use of 
adipose-derived stromal cells for reconstruction in post-mastectomy patients. According to 
the National Cancer Institute, 12.15% of woman will develop breast cancer in their lifetime. 
The safety of adipose-derived stromal cells for reconstruction was shown within the setting 
of breast cancer once active disease was eliminated  (Zimmerlan et al. 2011). In 2007, Cytori 
Therapeutics, Inc. received FDA approval for Celution® System apparatus which automates 
sorting of lipoaspirate to isolate adipose-derived stromal cells for the application of breast 
reconstruction. This device has already been used in Europe and Japan in the clinical setting 
and the application to breast reconstruction could be an avenue for a widespread clinical use 
of adipose-derived stromal cells meeting FDA approval.  
It is important for both clinicians and scientists to understand the current research with 
adipose-derived stromal cells given the great potential these cells have for future 
therapeutics. Therefore, we will cover the current research with adipose-derived stromal 
cells and their potential for osteogenic and adipogenic differentiation along with some of the 
major relevant pathways leading to their differentiation. In addition, we will cover different 
scaffolds that have been used to place these cells within the three-dimensional network of 
the surrounding tissue. Finally, we will discuss possible directions for future research.  
2. Adipose-derived stromal cells and osteogenesis 
The generation of skeletal tissue remains an elusive clinical goal of regenerative medicine. 
The relative paucity of available donor sites for autogenous bone grafts limits their use in 
clinical application. The need for bone replacement is increasing with an aging population, 
leading to an increase in the number of patients diagnosed with osteoporosis with 
subsequent fractures. In addition, the treatment of non-union fractures across all ages and 
populations remains a high biomedical burden. Since the isolation and characterization of 
adipose-derived stromal cells, significant work has been done defining protocols for 
inducing osteogenic differentiation within this population of multipotent cells.  
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2.1 In vitro methods of human and mouse adipose-derived stromal cell harvest 
Adipose derived stromal cells can be harvested following a liposuction procedure or an 
adipose tissue resection. While surgeons initially believed ultrasonic techniques would have 
a negative effect on adipose-derived stromal cell viability, it has been shown that they retain 
their osteogenic capacity following ultrasonic assisted liposuction (Panetta, et al, 2009). The 
other major difference between harvesting adipose-derived stromal cells after a liposuction 
procedure rather than an adipose tissue resection is the use of tumescent or saline fluid that 
is injected prior to liposuction procedures.  This injection decreases surgical bleeding and 
makes the procedure technically easier to perform. However, the additional fluid injected 
during lipoaspiration dilutes the adipose-derived stromal cells, and thus the total number of 
adipose-derived stromal cells able to be isolated in liposuction tissue. Therefore, adipose-
derived stromal cells harvest yields following a lipoaspiration procedure are often less than 
following an adipose tissue resection. 
Once the lipoaspirate is collected, the stromal cells within the heterogeneous population of 
cells within the lipoaspirate must be isolated. The adipose tissue settles into two layers 
consisting of the supernatant, which contains suctioned adipocytes along with stroma and 
the bottom layer of liposuction aspirate fluid containing larger pieces of lipoaspirate (Levi & 
Longaker, 2011). Adipose-derived stromal cells can be isolated from either layer, but there is 
a higher yield of stromal cells from the adipocyte supernatant (Yoshimura, et al. 2006). From 
there, adipose-derived stromal cells are isolated though a series of digestion, washing, 
straining, and neutralizing steps (Yu, et al. 2011) through readily available protocols. Once 
the progenitor cells are isolated, they can be plated for in vitro expansion and manipulation 
in culture or direct injection into a defect site.  
Adipose-derived stromal cells have been shown to be similar in profile to bone marrow and 
umbilical cord blood derived stem cells (Kern, et al. 2006). Adipose-derived stromal cells 
were first characterized by their ability to differentiate into certain mesenchymal cell 
lineages. Using flow cytometry analysis, researchers have attempted to define these stromal 
cells by specific cell surface markers. However, generating a defined list of concrete markers 
has been a challenge. This is likely due to variability in patient profile and number of in vitro 
passages along with variability in stages of differentiation. Despite these difficulties, the 
International Society for Cellular Therapy released a position paper in 2006 stating that the 
minimal criteria for being classified as a mesenchymal stromal cell according to cell surface 
markers to include the expression of CD105 (Endoglin), CD73, and CD90 while lacking 
expression of hematopoietic markers CD45, CD34, CD14, CD11b, CD79┙, CD19, and HLA-
DR (Dominici M, et al. 2006).  
2.2 Osteogenic in vitro differentiation protocols 
The cocktails used for osteogenic differentiation do not vary as much as those for adipogenic 
differentiation.  In general, all osteogenic media protocols utilize β-glycerol phosphate and 
ascorbic acid, albeit in slightly different concentrations (Table 1).  Interestingly, mouse 
adipose-derived stromal cells have been shown to be less osteogenic than human adipose-
derived stromal cells when using these two components alone.  Studies have shown that 
mouse adipose-derived stromal cells require an additional osteogenic stimulus, such as 
retinoic acid (Wan, et al. 2006).  Moreover, growth factors such as fibroblast growth factor 
(FGF)-2 inhibit the osteogenic differentiation of mouse adipose-derived stromal cells, while 
human adipose-derived stromal cells osteogenic differentiation proceeds relatively 
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unabated in the presence or absence of FGF-2 (Quarto & Longaker 2006; Quarto & Longaker 
2008).  Interestingly, preliminary data from our group has demonstrated that TGF-β acts to 
inhibit both osteogenesis and adipogenesis in mouse adipose-derived stromal cells. Instead, 
it seems that TGF-β acts to drive mouse adipose-derived stromal cells toward a 
chondrogenic fate (James, et al, 2009; Xu, et al. 2007).  TGF-β has also been shown to inhibit 
osteogenic human adipose-derived stromal cell differentiation in large doses. Additionally, 
while retinoic acid can be utilized to augment mouse adipose-derived stromal cells 
differentiation, it has little effect on the ability of human adipose-derived stromal cells to 
undergo osteogenic differentiation (Levi, et al, 2010a; Wan, et al, 2007a) Human adipose-
derived stromal cells osteogenic differentiation can, however, be enhanced by 
supplementation with several cytokines, such as Insulin Like Growth Factor (IGF) (Levi & 
Longaker 2010a), Platelet Derived Growth Factor Alpha (PDGF-α)(Levi & Longaker 
2010a), Sonic Hedgehog (SHH) (James, et al. 2010), or Bone Morphogenetic Protein-2 
(Knippenberg M, et al. 2006). 
 





(in mouse ASCs) 
1-10 uM 
Sonic Hedgehog Stimulatory 100-750 ng/ml 
BMP-2 Stimulatory 50-200 ng/ml 
BMP-4 Stimulatory 10-50 ng/ml 
IGF-1 Stimulatory 25-50 ng/ml 
PDGF-α Stimulatory 10-20 ng/ml 
Noggin Inhibitory 100-400 ng/ml 
BMPR-IB/ALK-6/Fc Chimera Inhibitory 0.5-2.0 ug/ml 
Table 1. Stimulatory and Inhibitory Cytokines for ASCs for use in Osteogenic Differentiation 
Media 
For osteogenic differentiation, cells should be plated in a 6-well plate (80,000-100,000 cells 
per well), a 12-well plate, (35,000-45,000 cells per well), or a 24-well plate (15,000-25,000 cells 
per well).  After attachment, adipose-derived stromal cells can be cultured in osteogenic 
differentiation medium.  
Early and late osteogenic differentiation has been defined to occur at specific time points, 
and these time points vary between species. While mouse adipose-derived stromal cells 
undergo early osteogenesis after 7 days in culture and late osteogenesis after 14 days in 
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culture. In contrast, human adipose-derived stromal cells begin to differentiate much earlier 
than mouse adipose-derived stromal cells and show evidence of early and late osteogenesis 
following 3 and 7 days in culture, respectively.  RNA analysis of adipose-derived stromal 
cells for specific osteogenic gene markers is a commonly used method to assess osteogenic 
differentiation in a quantitative manner. Specific gene markers for early osteogenic 
differentiation include Alkaline Phosphotase (ALP), Runt Related Protein-2 (RUNX-2), and 
Collagen Ia1 (COL1A1). Gene markers for intermediate and late osteogenesis include 
Osteopontin (OPN) and Osteocalcin (OCN), respectively.  Alkaline phosphatase staining and 
quantification is another method used to assess early osteogenic differentiation of adipose-
derived stromal cells (day 3 for human adipose-derived stromal cells, day 7 for mouse 
adipose-derived stromal cells). Late osteogenic activity can be assessed by Alizarin red or 
Von Kossa staining, which are assays for extracellular mineralization (day 7 in human 
adipose-derived stromal cells, day 14 in mouse adipose-derived stromal cells).  
2.3 Molecular pathways of differentiation 
There are several key molecular pathways that lead to the differentiation of a multipotent 
cell into a mature osteoblast in the process of osteogenesis. Runx-2 is considered the 
principal osteogenic switch and has a key role in the commitment of stem cells into an 
osteoblastic lineage. Runx-2 null mice show a complete deficiency in skeletal formation 
(Komori and Kishimoto, 1998). Runx-2 is transcriptionally upregulated by the bone 
morphogenetic proteins (BMP) through transduction via Smad 1 and 5 (Chen et al, 2004). 
Retinoic acid has also been shown to increase Runx-2 expression and stimulate mouse 
adipose-derived stromal cell osteogenic differentiation by increasing the expression of 
BMPR-IB protein (Wan, Longaker 2006).  While Transforming Growth Factor-Betas (TGF- 
┚s) have been shown to be increased during bone development and growth, their effect on 
precursor cell differentiation into osteoblasts depends on cell type, stage of differentiation, 
and levels of expression (Linkart 1996, Komori 2002).  
The Wnt signaling pathway is a group of proteins involved in a wide array of 
developmental and cellular processes. In the canonical Wnt pathway, Wnts bind to cell-
surface receptors of the Frizzled family and their co-receptors, low-density lipoprotein 
receptor related protein (LRP), leading to inactivation of the axin-glycogen synthase kinase 
3┚ complex which stabilizes Beta-catenin. Beta-catenin translocates into the nucleus to 
promote Wnt gene expression. LRP5 knockout mice show a phenotype with low bone mass 
(Gong et al, 2001) while overexpression of the same gene is associated with high bone mass 
(Boyden et al, 2002). Wnt3A has been shown to have differing results on osteogenic 
differentiation depending on dosage and level of baseline differentiation along with age of 
the cells. (Quarto, Longaker 2010). Low dose treatment with Wnt3a enhanced bony 
regeneration in a mouse critical calvarial defect treated with differing doses of Wnt3a in 
juvenile mice, while higher doses decreased repair (Quarto, Longaker 2010). Conversely, in 
adult mice, increasing doses of Wnt3a enhanced bone regeneration.   
In the non-canonical Wnt pathway, Wnts bind to the receptors Frizzled and Dishevelled but 
the non-canonical pathway does not mediate its signal through the glycogen synthase 3┚ 
kinase complex or the Beta-catenin complex, but rather through G-proteins and GTPases. 
While the most studied aspect of the non-canonical Wnt pathway is their regulation in cell 
polarity, a growing body of evidence suggests that this pathway is important in bone 
development. Wnt5a has been shown to increase osteoblast formation from human bone 
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mesenchymal stem cells in vitro (Baksh & Tuan, 2007). In human adipose-derived stromal 
cells, the addition of Wnt5a in vitro increased the expression of Runx2 and osteocalcin and 
mineralized nodule formation (Santos, et al, 2010).  
2.4 Growth factors and hormones that promote osteogenesis 
Growth factors are signaling molecules that have a wide effect on cellular processes. The 
majority of growth factors are secreted as proteins or hormones and act in an autocrine, 
paracrine, or endocrine manner to affect cellular proliferation and differentiation by 
regulating gene expression, protein synthesis, and cell signaling. Through the modulation of 
specific growth factors, osteogenesis can be enhanced with the result of improved skeletal 
healing.  
Bone morphogenetic proteins are a group of secreted cytokines that belong to the 
Transforming Growth Factor-┚ superfamily. Throughout history, skeletal tissue was 
known for its ability to regenerate and efforts were undertaken to try to isolate an 
intrinsic property secreted by these cells that led to their regenerative properties. BMPs 
were first discovered and named in 1965 (Urist, 1965) and the first BMP gene was isolated 
and cloned by Wozney in 1988 (Wozney et al, 1988). In 2002, the FDA approved the use of 
recombinant BMP-2 to be used on a three-dimensional scaffold for anterior lumbar fusion 
(McKay et al, 2007). Today, over twenty different genes belong to the BMP family mainly 
involved in the regulation of bone and cartilage formation (Bessa C et al. 2008). The BMP 
proteins signal (Fig. 1) through BMP receptor Type I and II, which leads to the 
phosphorylation of receptor-regulated SMAD 1,5, and 8, which combine with the 
common-mediator SMAD 4. This complex then migrates into the nucleus to affect gene 
expression.  
A large body of research has validated the importance of BMP-2’s role in bone formation 
and healing. BMP-2 has been shown to induce chondrocyte and osteoblast precursor 
formation in mesenchymal stem cells (Wall et al. 1994) and specifically shown to induce 
osteogenic differentiation in adipose-derived stromal  cells (Dragoo et al. 2003) in vitro. Our 
group (Cowan, Longaker 2005) showed the use of BMP-2’s effect combined with adipose 
derived stromal cells in vivo on bony healing by culturing adipose-derived stromal cells with 
rhBMP-2 for 4 weeks prior to implantation onto a PLGA scaffold into a critical-sized 
calvarial defect in a mouse. With the treatment of BMP-2 ex-vivo, cells treated with 
recombinant human BMP-2 showed accelerated healing over unstimulated scaffolds with 
complete healing in as little as two to four weeks as demonstrated by histology and 
microCT. Interestingly, prolonged exposure to recombinant human BMP-2 was also shown 
to increase osteoclast activity and increase bone turnover and resorption. Therefore, to avoid 
increased bone turnover, our group used direct in vivo injection of recombinant human 
BMP-2 without the prolonged ex-vivo treatment (Levi, Longaker, et al 2010b) into a critical 
calvarial defect with and without adipose-derived stromal cells. Cells treated with 
recombinant human BMP injected subcutaneously into the skeletal defect on post-op days 1-
3 showed increased healing at 8 weeks over unstimulated scaffold alone and untreated cells. 
The increase in osteogenesis was observed with this method of BMP-2 augmentation, but 
without the stimulation of osteoclast-induced bone turnover and resportion. The current 
scope of research is concentrating on how to deliver BMP-2 into the skeletal wound 
microenvironment to promote osteogenesis and bony healing while minimizing side effects 
such as ectopic bone formation (Zara, Siu, Soo et al. 2011).  
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Fig. 1. Bone Morphogenetic Protein Pathway 
BMP ligand binds to BMP-R1 or 2, which phosphorylates SMAD 1,5, and 8. Co-smad 4 
complexes with Smad 1,5, and 8 and translocates into the nucleus and regulates gene 
expression   
In addition to BMP-2, BMP-7 (Osteogenic Protein-1) has also been shown to be effective in 
the augmentation of skeletal healing. In a monkey model, recombinant human BMP-7 was 
injected into a scaffold at the skeletal injury site and demonstrated healing in an 
ulnar/tibial segmental defect model. (Cook, et al 1995).  A randomized clinical trial 
compared the use of BMP-7 versus autogenous bone graft in the treatment of tibial non-
unions (Friedlaender, 2004) and found that using BMP-7 was equivalent in clinical 
outcomes without the morbidity of using an autogenous bone graft. Specifically with 
adipose-derived stromal cells, researchers using an adenovirus vector ex vivo to induce 
BMP-7 expression showed increased bone formation both in vitro and in vivo using rat 
adipose-derived stromal cells (Yang, et al. 2005) and in human adipose-derived stromal 
cells (Kang Y, et al. 2007). 
The fibroblast growth factor family has over twenty members and four receptors involved in 
diverse cellular processes from angiogenesis to wound healing. Similar to the BMP family, 
fibroblast growth factors have been shown to have a significant effect on osteogenesis 
(Ornitz and Marie, 2002). In particular, FGF-2 is expressed in osteoblastic cells and has been 
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shown to have important functions in the regulation of bone and cartilage formation. FGF-2 
knockout mice show decreased bone mass and bone formation compared to control mice 
(Montero et al. 2000).  Initial work on the effect of FGF-2 on adipose-derived stromal cells 
showed that FGF-2 expression was critical in maintaining clonogenicity and differentiation 
potential (Zaragosi et al. 2006) along with the maintenance of adipose-derived stromal cells 
proliferation in vitro (Quarto and Longaker, 2006). Evaluation of FGF expression during 
osteogenic differentiation of adipose-derived stromal cells showed that FGF-2 is down-
regulated during osteogenic differentiation (Quarto and Longaker, 2008) while FGF-18 is 
upregulated. This was explored further by examining different isoforms of FGF-2. The high 
molecular weight protein form of FGF-2 increased expression during osteogenesis while the 
low-molecular weight form decreased, suggesting a regulation at the translational level in 
the balance between maintaining multipotency and lineage commitment. In order to explore 
the effects of FGF-2 in vivo, we engineered feeder cells capable of secreting the FGF-2 protein 
when driven by the presence of a synthetic ligand, Shield-1, which stabilizes a protein-
destabilizing domain fused to the FGF-2 gene (Kwan, Longaker, 2011). Feeder cells and 
adipose-derived stromal cells were both seeded on a scaffold and placed into a mouse 
critical-sized calvarial defect. Shield-1 was delivered intraperitoneally and the mice were 
followed up to 20 weeks. There was significantly improved healing with FGF-2 versus the 
non-injected group of control adipose-derived stromal cells and scaffold alone in the defect. 
A possible explanation for the improved osteogenesis and calvarial defect healing in vivo 
may be linked to the increased proliferation of osteoprogenitor cells due to FGF-2 
expression.  
Insulin-like growth factors are proteins with sequence homology similar to insulin under the 
control of growth hormone. There are two types, IGF-1 and IGF-2, which play a wide 
variety of cellular roles from the regulation of proliferation to apoptosis. Both IGF-1 and 
IGF-2 have been shown to be associated with increase in bone formation and density  
(Adami et al. 2010, Chen et al, 2010) while their reduction has been shown to be associated 
with decreased bone density (Bennett, 1984). In order to specifically identify genes 
upregulated during osteogenesis, our group isolated RNA from human adipose-derived 
stromal cells during in-vitro osteogenesis and performed a microarray analysis (Lee, 
Longaker, 2010). Gene expression of IGF-1 was found to be elevated 3.5 fold from baseline 
levels at day three of osteogenic differentiation with the microarray. IGF-1’s ability to 
increase osteogenesis was then tested by augmenting osteogenic differentiation media with 
IGF-1 in vitro (Levi, Longaker 2010a). Alkaline phosphatase activity was elevated with the 
addition of IGF-1 and there was increased matrix mineralization evident with the treated 
group stained with alizarin red. Quantitative real-time polymerase chain reaction showed 
elevated levels of Runx2 and Osteocalcin when adipose-derived stromal cells were treated 
with IGF-1.   
The effect of estrogen on bone formation is well known. Decreasing levels of estrogen are 
one of the main culprits in the pathogenesis of osteoporosis with estrogen withdrawal 
causing an increase in bone remodeling (Seeman, 2003). While men do not have a 
comparable deceleration of hormone production, circulating levels of free estrogen also 
declines with men with aging leading to comparable long term loss of trabecular bone 
(Seeman, 2004). The addition of estrogen through 17-┚ estradiol increased levels of 
osteogenesis in human bone marrow mesenchymal stem cells through modulation of 
estrogen receptor ┙ and ┚ (Hong, et al 2006). Human adipose-derived stromal cells 
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augmented with 17-┚ estradiol in vitro showed increased evidence of osteogenesis through 
increased expression of alkaline phosphatase and osteocalcin as compared to control cells 
without estrogen augmentation (Hong et al, 2007).  
The effect of androgens on bone formation is less clear. It is recognized that patients with 
androgen deficiency have lower bone mass and higher bone turnover compared to patients 
with normal levels of androgen (Hofbauer & Khosia, 1999). The majority of in vitro studies 
indicate that testosterone and dihydrotestosterone have proliferative effects on osteoblast 
progenitors, but there is no consensus as to whether androgens promote or inhibit 
osteogenic differentiation (Vanderschueren, et al, 2004). Androgen replacement therapy in 
vivo has shown to be effective in increasing bone mass in hydogonadal patients, the effect is 
mitigated in patients with more modest decreases in testosterone (Vanderschueren, et al, 
2004). The full effects of estrogen and androgen and differences in sex hormones still must 
be worked out as well as the effect of sex of the donor adipose-derived stromal cells in 
differences on osteogenic differentiation.  
2.5 Gene therapy  
Another strategy for improving osteogenic differentiation is gene therapy to either express 
or knockdown specific proteins for the desired effect altering cellular function. Strategies in 
genetic therapy include in vivo direct gene delivery using a vector for transfection or ex vivo 
techniques, which involves treating the cell of interest with modification of the genome 
outside of the host prior to implantation.  
Gene therapy requires a vector to transfer the genetic material into the target cell. Vectors 
can be divided into viral and non-viral and also whether the strategy integrates the vector 
into the host-genome or is based on a transient effect. Viral vectors have the advantage of 
being efficient in their ability to infect host cells. Common viral vectors are adenovirus, 
lentivirus, and retrovirus. While the integrating viral vectors are efficient and express the 
DNA of question for the life of the cell, there is no way to completely control the site of 
integration leading to concern regarding mutations and oncogenic activity. Viral vectors 
can also elicit a host immune response causing rejection. Non-integrating strategies such 
as liposome based particles and electroporation transiently transfect the cells and have a 
decreased immune response, but are not as efficient and have variable expression.  
Zhang et al. (2006) used an adenovirus vector to overexpress Runx-2 in mouse adipose-
derived stromal cells to increase osteogenesis in vitro and in vivo by implanting seeded 
scaffolds on the back of nude mice. Several strategies have used BMP-2 gene therapy to 
promote bone healing and osteogenic differentiation. A segmental defect created in New 
Zealand white rabbits was treated with adenoviral vectors expressing BMP-2 resulting in 
increased healing in the treatment group (Baltzar, 2000). Lee SJ et al (2010) created a 
bicistronic vector for co-delivery of both Runx-2 and BMP-2 into human adipose-derived 
stromal cells. Using microporation for their transfection strategy, they showed increases in 
osteogenesis in vitro and implanted transfected human adipose-derived stromal cells on a 
PLGA scaffold subcutaneously in vivo showing increase in ectopic bone formation compared 
to control.  
Osterix is a zinc finger transcription factor that is expressed in osteoblasts whose role is 
critical during osteoblast differentiation. Nakashima et al. (2002) first identified osterix 
through a screen of expressed genes during osteogenic differentiation. Through homologous 
recombination, they produced osterix-null mice, which showed no bone formation. Osterix 
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appears to be downstream of Runx-2 as osterix-null mice had normal Runx-2 expression and 
normal cartilage formation. However, Runx-2 negative mice show impaired chondrogenesis 
and decreased osterix expression. Overexpression of osterix has been shown to increase 
osteogenic differentiation in embryonic stem cells by increased in levels of Osteocalcin and 
Runx-2 (Tai, et al. 2004) and in adipose-derived stromal cells  (Wu L, et al 2007). Lee SJ et al. 
(2011) used electroporation to co-transfect Runx-2 with osterix into adipose-derived stromal 
cells. Transfected cells with osterix alone and osterix with Runx-2 both showed significant 
increase in osteogenesis over control cells.  
Msx-2 (Hox-8) is a homeodomain transcription factor that functions as a transcriptional 
regulator of the osteocalcin promoter (Towler DA, et al 1994). Msx-2 has been found to be 
vital in craniofacial development, as mutations within the homeodomain of Msx-2 have 
been shown to lead to craniosynostosis, the premature fusion of calvarial sutures (Jabs, et al. 
1993; Liu et al. 1995). Msx2 null mice have deficient endochondral bone formation, defects in 
skull ossification and a persistent calvarial foramen (Satokata, et al, 2000). Using CMV-Msx2 
transgenic mice, Cheng et al, (2008) showed that overexpression of Msx2 leads mesenchymal 
progenitor cells into an osteogenic lineage enhancing osteoblast formation along with 
trabecular bone formation by activation of the canonical Wnt pathway. 
In looking for specific genetic targets to augment adipose-derived stromal cells for 
osteogenic differentiation, our group focused on the noggin protein, which is an inhibitor 
of BMP signaling. We evaluated the effect of noggin suppression on osteoblast 
differentiation by using siRNA constructs against the noggin protein in primary 
osteoblasts (Wan, Longaker et al, 2007b). Noggin suppression was confirmed using 
western blot and QT-PCR. Evaluation of BMP signaling in vitro with cells transfected with 
Noggin siRNA constructs showed an increase in BMP signaling with Smad1/5 along with 
evidence of osteogenic differentiation of preosteoblasts as compared to control. Noggin 
knockdown also increased skeletal healing in vivo when osteoblasts transfected with 
Noggin siRNA were seeded on a PLGA scaffold as demonstrated by microCT and 
histomorphometric analysis.  
3. Adipogenesis and adipose-derived stromal cells 
The adipogenic differentiation of multipotent stromal cells is of interest to many specialties 
of medicine. The growing body of research in obesity and adipose biology has opened the 
field of adipogenesis to numerous specialties in clinical medicine and science. Stem cell 
scientists, bone biologists, endocrinologists, and tissue engineers all have a vested interest in 
the study of adipogenesis. From a clinical standpoint, surgeons are faced with challenging 
reconstructive cases in patients afflicted with soft tissue deficiencies. For example, burn 
patients often have soft tissue atrophy and severe skin contractures and would greatly 
benefit from soft tissue augmentation.  Similarly, the widespread use of HAART (Highly-
active retroviral therapy) medications for HIV has left many HIV patients with facial 
lipodystrophy, which can be disfiguring and socially troublesome. In the pediatric 
population, patients with congenital malformations would greatly benefit from new soft 
tissue engineering techniques. For example, Parry-Romberg disease causes progressive 
hemifacial soft tissue atrophy in the face. Outcomes of these patients would greatly improve 
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3.1 Adipogenic in vitro differentiation protocols 
The adipogenic differentiation protocols of primary mesenchymal stromal cells vary as 
reported in the literature. For the purposes of this chapter, two of the most commonly 
studied mesenchymal stem cells populations were examined: bone marrow mesenchymal 
stem cells and adipose-derived stromal cells. Generally, a three component cocktail is used 
to supplement media for bone marrow mesenchymal stem cell adipogenic induction, 
including Insulin, Dexamethasone, and IBMX (3-isobutyl-1-methylxanthine). There are 
several differences between mouse and human adipogenic differentiation protocols. For 
example, Insulin was not used in the majority of publications in human bone marrow 
mesenchymal stem cell adipogenic differentiation protocols, while insulin is present in the 
majority of murine adipogenic differentiation protocols. Additionally, human adipogenic 
protocols used an increase in dexamethasone along with the addition of Indomethacin in 
comparison to mouse bone marrow mesenchymal stem cell protocols. 
Adipose-derived stromal cells are multipotent mesenchymal cells and thus can be 
differentiated into adipocytes.  With regards to adipose-derived stromal cell adipogenic 
differentiation, there are a wide variety of reports of varied differentiation cocktails with 
many published articles in the last year (Romo-Yanex, et al 2011;  Ghosh, et al, 2010; James, 
et al. 2010; Valorani, et al, 2010, Lee JE, et al. 2010). Generally, a three or four component 
cocktail is used for adipose-derived stromal cell adipogenic differentiation, including 
Indomethacin, Insulin, Dexamethasone and IBMX.  Similar to bone marrow mesenchymal 
stem cell adipogenesis protocols, there are a wide variety of recommended cocktails that 
become even more heterogeneous when comparing protocols for mouse adipose-derived 
stromal and human adipose-derived stromal cell adipogenesis. For example, though insulin 
concentrations in the adipose differentiation media of both mouse adipose-derived stromal 
cell and human adipose-derived stromal cell are relatively similar, an approximate 10-fold 
increase in dexamethasone concentration exists in mouse adipose-derived stromal cell 
adipogenesis protocols when compared to human adipose-derived stromal cell protocols 
3.2 Molecular pathways of differentiation 
At the molecular level, several key genes are expressed during the differentiation of pre-
adipocytes to mature adipocytes including lipoprotein lipase (LPL), peroxisome 
proliferator-activated receptor (PPAR┛), and enhancer binding proteins (EbP) (Kronenberg 
& Williams, 2008). In addition, several Hox genes have been recently identified that are 
highly expressed during the adipogenic differentiation of human adipose-derived stromal 
cell (Cowherd, et al. 1997; Cantile, et al. 2003). Other genes such as TAZ have been shown to 
activate the Runx-2 transcription factor and stimulate osteogenesis while inhibiting 
adipogenesis (Hong, et al. 2005).  
PPAR┛ is one of the most widely studied genes involved in adipogenesis, and has been 
translated for clinical use in the form of the agonist rosiglitazone, as well as the similar 
agents (troglitazone, etc). These PPAR┛ agonists have been used in the treatment of diabetes 
as they have been shown to speed up the differentiation process of pre-adipocytes or 
adipoprogenitor cells in vitro. Rosiglitazone functions by binding to PPAR┛, thus 
‘sensitizing’ adipocytes to insulin (Mayerson, et al 2002). One of the major side effects of this 
class of pharmaceuticals is bone mineral density reduction, which is thought to be due to the 
diversion of mesenchymal stem cells to adipogenesis rather than osteogenesis in vivo 
(Bodmer, et al, 2009; Rosen, et al. 2006). To the full extent that rosiglitazone is able to induce 
www.intechopen.com
  
Tissue Engineering for Tissue and Organ Regeneration 
 
118 
mesenchymal stem cell adipogenesis as a single agent is unknown. However, it is believed 
that this class of drugs is capable of enhancing the differentiation of pre-adipocytes to 
adipocytes in vivo (Ninomiya, et al 2010). Thus, PPAR┛ agonists may be useful in adipocyte 
induction cocktails for adipose-derived stromal cells. Furthermore, from a clinical 
standpoint, targeting the PPAR┛ pathway may improve the adipogenic potential of 
transplanted stem cells further improving soft tissue engineering outcomes.  
One of the surgical limitations of fat transfer is the high rate of adipocyte resorption over 
time. It is thought that adipocyte resorption during fat transfer is due to the inadequate 
blood supply and thus, surgeons have set out to improve circulation to transplanted 
adipocytes. Besides alterations in technique, recently, Yoshimura et al has reported 
enhanced adipocyte viability and vascularization when seeding adipocytes with human 
adipose-derived stromal cells from the same patient at the time of surgery (Suga et al 2010, 
Yoshimura, et al. 2008, Yoshimura, et al. 2009, Matsumoto, et al. 2006). This technique offers 
the use of an autologous scaffold seeded with autologous multipotent stromal cells.  Human 
adipose-derived stromal cells are a known vasculogenic cell type that have been shown to 
secrete vasculogenic cytokines, thus working in an autocrine and paracrine fashion to allow 
for improved survival of adipocytes and enabling possible adipogenic differentiation.  
Therefore, potential benefits of using human adipose-derived stromal cells to differentiate 
into adipocytes, include their ability to proliferate after transplantation, their release of 
angiogenic cytokines, and their ability to differentiate into endothelial cells and undergo 
neovascularization (Planat-Barnard et al., 2004; Miranville, et al. 2004, Moon, et al. 2006) 
4. Scaffold technology and adipose-derived stromal cells 
Almost as important as the proper engineering of multipotent cells into the desired lineage 
is their placement within the three-dimensional context of the target organ. This is especially 
true with skeletal and soft tissue engineering as their structure is critical to their function. 
Recent advancements in the design and quality of scaffold technology is critical for the 
advancement of successful in vivo application of multipotent cells. With the goal of 
engineering functional tissue, biomimetic scaffolds are designed to provide 3-dimensional 
structural support for the engineered tissue, uniform pore size and structure for a matrical 
distribution of cells, and combinations of substrates and growth factors to promote viability 
and differentiation along the appropriate cell lineage.  With technologies enabling the 
reliable production of mineralized biopolymers to nanospun fibers, scaffolds engineered 
from these materials promote healing in vivo, (Lew, et al. 1997; Osathanon, et al. 2009) and 
prove a powerful delivery system for adipose-derived stromal cells in the generation of 
functional tissue replacement.   
The growing incidence of craniofacial bone defects arising from congenital malformation, 
surgical resection and trauma necessitates the development for skeletal regeneration of bony 
defects to restore functional movement and protection to the head and its critical structures. 
Regenerated bone exists in a dynamic environment and must provide adequate structural 
support and tensile strength. One of the important models for skeletal regeneration in the 
craniofacial context is the critical size calvarial defect, in which a bony deficit is created in an 
animal model that is of a size that will not heal within the lifetime of an animal.  Thus, any 
healing observed is due to the experimental contribution.  Because of the availability of 
experimental animals and analytical tools, the laboratory mouse is a common model for 
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bone regeneration in calvarial critical-sized defects, which are between 3-4mm in diameter 
(Mooney & Siegel, 2005).  
Critical to the engineering of an ideal scaffold for bone regeneration are the 
biocompatibility, osteoconductive, and osteoinductive properties of the materials.  A 
biocompatible scaffold should be manufactured under sterile conditions, have an even and 
consistent pore size and distribution, and be non-toxic to the host tissues as it breaks down 
over time.  Osteoconductive properties refer to the characteristics of the scaffold framework 
and its impact on the resulting structure of newly formed bone, while osteoinduction is the 
promotion and induction of host or donor cells toward mature osseous formation. A variety 
of inorganic polymers and synthetic nanofibers are being used as the basis for 
manufacturing scaffolds and vary in their capability for osteoinduction, rate of resorption, 
and moldability.  
Polylactide (PLA) and poly lactic-co-glycolic acid (PLGA) polymers have been shown to be 
safe in human tissue (Frazza & Schmitt, 1971) and are resilient to fracture but lack significant 
osteoconduction.  Calcium phosphate and calcium sulfate salts, on the other hand, tend to 
be brittle and difficult to mold but contain natural bone elements of crystal salts found in 
bone matrix and tend to be more osteoconductive scaffolds than their polymer counterparts. 
 Of particular interest in this group is hydroxyapatite, a mineral salt composing a large 
proportion of naturally-occurring bone matrix with strong osteoconductivity (Chang, et al 
2000).  
In order to combine the tensile strength and load-bearing capabilities of a polymer scaffold 
with the osteoconduction and cellular substrate of mineral salts, Cowan et al employed a 
strategy combining osteogenic mouse adipose-derived stromal cells seeded on a PLGA 
scaffold coated with hydroxyapatite for bony regeneration of a 4mm critical-sized defect in 
mouse. (Cowan, et al, 2004)  The combined osteogenic potential of adipose-derived stromal 
cells and osteoconduction of apatite-coated PLGA promoted complete healing within 12 
weeks with major contribution from the transplanted adipose-derived stromal cells as 
shown by chromosomal analysis. Levi et al have recapitulated these results with apatite-
coated PLGA scaffolds in mouse calvarial defect using human adipose-derived stromal cells 
in immunodeficient nude mice, demonstrating the potential of human cellular therapy 
delivered on hybrid polymer mineral scaffold for translational development. (Levi, et al. 
2010b)   
Although significant bone regeneration has been achieved using osteoconductive scaffolds 
and adipose-derived stromal cells without the use of additional growth factors (Cowan, et al 
2004; Levi, et al. 2010b), the stimulation of well-characterized osteogenic pathways may 
enhance efficient new bone deposition in conjunction with biomimetic scaffolds and cell 
therapy.  Bone morphogenetic proteins (BMPs) along with valproic acid and other factors 
have demonstrated abilities to accelerate bone formation in vivo (Cowan, et al. 2005) and 
may be candidates for delivery in combination with ASCs and apatite-coated PLGA 
scaffolds for increased efficiency and reliability of osteogenesis. 
Similar to current clinical treatment modalities for bone defects, soft tissue deficits due to 
trauma, tumor, and congenital etiologies are treated with surgical grafts from autologous, 
allogenic, or alloplastic sources.  The successes of vascularized microvascular flap transfer, 
the gold standard modality, are often accompanied with limitations in source material and 
patient morbidity.  Because adipose tissue has numerous functions, including energy 
regulation, secretion of important paracrine and endocrine factors, and mechanical 
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protection, it is important to develop new strategies for replacement of functional soft tissue 
deficits. Of major consideration for clinical translation is the regeneration of adipose tissue 
following mastectomy, requiring adipose stroma and a biomimetic matrix for the 
replacement of breast tissue. 
Cellular transplants for adipogenic regeneration hinge on scaffolds that support cell 
adhesion and the differentiation and uptake of lipids while providing appropriate structural 
support.  Porosity is a critical factor in the scaffold structure to allow the development of 
angiogenic support necessary for functional tissue formation.  A number of synthetic and 
biological scaffolds have been studied as delivery systems of adipocyte precursor cells for 
effective adipose tissue generation with varying degrees of success and limitations. 
 Inorganic synthetics such as PLGA and polyglycolic acid (PGA) offer moldable, highly 
regular structures and non-toxic breakdown.  Gel-based delivery systems promote cell 
survival but lack the organizational regularity of inorganic scaffolds.  Natural proteins 
found in connective tissue such as collagen can be engineered into scaffold design with 
homogeneous structure and porosity, and mimic biological matrix found commonly in 
adipose tissue.   
Matrigel™ is a gel-like substance derived from animal connective tissue proteins and 
growth factors, and is readily available commercially.  Despite the translational barrier of its 
sarcoma derivation, Kawaguchi et al and others have reported successful angiogenesis and 
adipogenesis following injection of Matrigel™ in mouse fat pad (Kawaguchi, et al. 1998).  
The mixture of components in matrigel including collagen, laminin, and growth factors 
demonstrated sufficiency for the generation of new vascularized adipose tissue, but because 
of the stochastic organization of proteins within the gel, the distribution of cells in the de 
novo tissue reflect a scattered and uneven pattern of growth. Adipogenic tissue regeneration 
with eventual clinical translation in mind should promote predictable growth of new soft 
tissue.  An ideal scaffold would define the structure of the newly formed tissue to be 
populated by transplanted donor cells and stimulated endogenous pre-adipocytes and 
allow for angiogenic growth and support into newly forming tissue. 
One study performed a direct in vivo comparison of three disparate scaffold technologies for 
the delivery of mouse ASCs as an assay for adipogenic ability using PGA, collagen, and 
hyaluronic acid gel (Itoi, et al. 2010).  PGA represents the biodegradable synthetic group of 
scaffolds, extracellular matrix-derived collagen from tendon is a natural product that is 
prepped into porous sponges, and hyaluronic acid (HA) is a derivative of extracellular 
matrix of soft tissue involved in cell proliferation.  ASCs were harvested from GFP mice to 
allow visualization of transplanted cell proliferation and differentiation, grown in 
adipogenic supplemented media, and seeded into the respective scaffolds and transplanted 
into athymic mice.  In all groups tested, fluorescent cells were present at four weeks and a 
slight increase in angiogenesis was seen. In contrast, Oil Red O staining for triglycerides was 
positive only in PGA and collagen groups and negative in HA. At 8 weeks, the most robust 
GFP positive adipose-like tissue was detected in the collagen scaffold construct indicating 
that collagen served as the best adipogenic scaffold in this comparison. 
Promising data from Davidenko et al (2010) combines the naturally-derived extracellular 
matrix components collagen and hyaluronic acid into a hybrid cross-linked scaffold 
designed to provide an array of matrix protein components with the structural advantage of 
collagen.  Thus, this design allows for precise engineering of scaffold structure and porosity, 
even distribution of transplanted adipogenic cells, and physiochemical safety.  Pre-
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adipocyte cells were shown to proliferate and differentiate readily on the scaffold during in 
vitro adipogenic induction and gene analysis showed increased expression of Adipsin 
following differentiation.   
5. Future directions 
Given the abundant availability of lipoaspirate combined with a relatively simple procedure 
to harvest, adipose-derived stromal cells have a potential to be critically important in the 
generation of tissue for clinical use in a wide range of pathologies. While there is great 
promise for the use of these cells, significant hurdles remain before they become available 
for wide spread clinical application. The ultimate translational goal is the ability to harvest 
the lipoaspirate and be able to process and implant the cells into the area of need in the same 
patient during a single surgical procedure. Research in several key areas must happen prior 
to this scenario being realized.  
Currently, the process for sorting and isolating stem cells from the lipoaspirate is a manual 
process. The total number of cells typically obtained is around 300,000 cells per milliliter of 
lipoaspirate (Levi & Longaker, 2011). While this yield is higher then other adult-stem cell 
populations, the process can still be time consuming and labor intensive. For widespread 
clinical use to be possible, the ability to have an automated processing unit isolate the 
stromal cells in the lipoaspirate would be critical to decreasing the time and cost of this 
procedure. Cytori’s Celution® System was developed to automate the sorting process and 
takes around 1 hour to sort 250 ml of lipoaspirate. Using Flow Cytometry, the cells sorted 
using the Celution® system were found to be similar to cells isolated on a manual sort with 
the ability to differentiate into osteogenic and adipogenic cells (Lin, et al. 2008).  As more 
research is done characterizing specific populations within adipose-derived stromal cells, 
the technology should improve to better match and sort for specific populations of cells 
more likely to differentiate into the desired cell lineage.  
The importance of scaffolds and their ability to deliver cells into the proper niche 
environment has been stated. As the technology improves with scaffold development, they 
have become much more than inert materials where cells are placed, but rather can provide 
a highly inductive environment for cells to be “coached” towards a certain lineage. The 
ability to augment scaffolds with various growth factors and cytokines has been shown to 
improve healing within specific wound environments (Brown, et al. 2011). These scaffolds 
can have the advantage of release kinetics allowing for a controlled delivery of the growth 
factor of interest into the wound environment (Kwan, et al, 2011). The future of scaffold 
technology is moving towards the ability to induce genetic therapy within its three-
dimensional structure. The delivery of BMP-2 and BMP-7 through vectors within the 
scaffold structure into host cells has already proven to be effective (Nie, et al. 2007; Zhang, et 
al. 2011).  
6. Conclusion 
With the large clinical need for replacement tissue, adipose-derived stromal cells are easily 
obtained in large numbers and offer a viable option for future therapeutic application given 
their ability to differentiate into multiple cell lines. Through continued research into 
pathways of differentiation, the ability to maximize the yield of these multipotent cells will 
continue to improve. With the increased effectiveness of technology for the sorting and the 
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application of adipose-derived stromal cells, they could soon become an important clinical 
tool for the treatment of a wide range of clinical pathologies.  
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